DM
Therapeutic Areas
Sarepta Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ELEVIDYS (delandistrogene moxeparvovec-rokl) | Duchenne Muscular Dystrophy (DMD) | Marketed / Phase 3 |
| SRP-5051 (vesleteplirsen) | Duchenne Muscular Dystrophy (DMD) | Phase 2 |
| SRP-9003 | Limb-Girdle Muscular Dystrophy Type 2E/R4 | Phase 3 |
| SRP-6004 | Myotonic Dystrophy Type 1 (DM1) | Phase 1/2 |
| SRP-6005 | Facioscapulohumeral Muscular Dystrophy (FSHD1) | Phase 1/2 |
| EXONDYS 51 (eteplirsen) | Duchenne Muscular Dystrophy (DMD) | Marketed |
| VYONDYS 53 (golodirsen) | Duchenne Muscular Dystrophy (DMD) | Marketed |
| AMONDYS 45 (casimersen) | Duchenne Muscular Dystrophy (DMD) | Marketed |
Leadership Team at Sarepta Therapeutics
DS
Douglas S. Ingram
President and Chief Executive Officer
SM
Sandy Mahatme
EVP, Chief Financial Officer & Chief Business Officer
DL
Dr. Louise Rodino-Klapac
EVP, Head of R&D and Chief Scientific Officer
DG
Dr. Gilmore O'Neill
EVP, Head of R&D and Chief Medical Officer
MC
Michael Chambers
SVP, Chief Commercial Officer
WC
William Ciambrone
EVP, Technical Operations
DA
Dr. Arthur A. Levin
EVP, Head of Research and Development